Literature DB >> 6333960

Complement activation and impaired capacity to solubilize immune complexes or to prevent their formation in essential mixed cryoglobulinemia.

A Corvetta, P J Spaeth, P A Ghirelli, F Orecchioni, R Buetler, M Montroni, U E Nydegger.   

Abstract

The complement profile, the immune complex solubilizing capacity (ICSC), the immune complex precipitation inhibition capacity (ICPIC), the presence of cryoprecipitable material, and the presence of immune-aggregate- and non-immune-aggregate mediated C1q-binding activity was assessed in serum samples from 23 patients suffering from essential mixed cryoglobulinemia (EMC). No correlation between the levels of cryoglobulins and the clinical activity of EMC was found. The mean C1q-binding activity in EMC serum samples was abnormally elevated 28 +/- 29% (mean +/- SD). In six out of eight serum samples that contained C1q-binding material, evidence was obtained that such material was of the complexed immunoglobulin G (IgG) type. Among the levels of C1q, C1r, C2, C4, C3, C5, C6, C1-inhibitor, C3d, B, I, H, as well as the total hemolytic activity and the activity of the alternative pathway of the complement, the mean serum concentrations of C1, C2, and C4 and in consequence the mean total hemolytic activity were significantly reduced, whereas the mean levels of C3d were significantly elevated in the EMC serum samples. The capacity of the 23 EMC serum samples to solubilize preformed immune precipitates from bovine serum albumin (BSA) and rabbit anti-BSA antibodies as well as their capacity to prevent the formation of the precipitable form of such complexes was analyzed. Compared to the ICSC and the ICPIC of 30 normal human sera, the ICSC and the ICPIC of EMC serum samples were reduced to 57 +/- 24% and 38 +/- 33%, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6333960

Source DB:  PubMed          Journal:  Diagn Immunol        ISSN: 0735-3111


  4 in total

1.  Cold-dependent activation of complement: recognition, assessment, and mechanism.

Authors:  K P Mathews; R A Mentyka; S L Chambers; T E Hugli; J H Herschbach; B L Zuraw
Journal:  J Clin Immunol       Date:  1992-09       Impact factor: 8.317

2.  Extreme hypercomplementemia in the setting of mixed cryoglobulinemia.

Authors:  Bharath Manu Akkara Veetil; Thomas G Osborn; Dean F Mayer
Journal:  Clin Rheumatol       Date:  2011-01-07       Impact factor: 2.980

3.  Formation of soluble immune complexes by complement in sera of patients with various hypocomplementemic states. Difference between inhibition of immune precipitation and solubilization.

Authors:  J A Schifferli; G Steiger; G Hauptmann; P J Spaeth; A G Sjöholm
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

Review 4.  The kidney in mixed cryoglobulinemias.

Authors:  D J Cordonnier; J C Renversez; P Vialtel; E Dechelette
Journal:  Springer Semin Immunopathol       Date:  1987
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.